Posted by Michael Wonder on 20 Feb 2025
AskBio receives FDA regenerative medicine advanced therapy designation for Parkinson’s disease investigational gene therapy
19 February 2025 - Regenerative medicine advanced therapy designation follows Phase Ib 36 month data.
AskBio today announced that investigational gene therapy AB-1005 for the treatment of Parkinson’s disease has been granted regenerative medicine advanced therapy designation from the US FDA.
